Elanco
ELAN
$25.13
+0.52%
Elanco Animal Health is a global animal health company that develops, manufactures, and markets pharmaceutical products for companion and food animals, operating in the Drug Manufacturers - Specialty & Generic industry. As a spin-off from Eli Lilly in 2018, it has grown through acquisitions including Bayer Animal Health, positioning itself as a top-tier player in the animal health sector. The current investor narrative centers on the company's turnaround execution, highlighted by strong Q1 2026 earnings, product momentum, and raised guidance, which have driven significant stock appreciation. Debate remains around the sustainability of margin improvement and debt reduction following its acquisition-heavy strategy.…
ELAN
Elanco
$25.13
Related headlines
Investment Opinion: Should I buy ELAN Today?
Rating: Buy. Thesis: Elanco is a turnaround play with strong product momentum, improving margins, and significant upside to analyst targets, but investors must monitor debt reduction and profitability trajectory. The consensus is bullish with 5 analysts maintaining positive ratings and an average price target implying ~29% upside.
Supporting Evidence: The forward PS ratio of 1.86x is below the trailing 2.38x, indicating expected revenue growth. Revenue grew 12.2% YoY in Q4 2025, and gross margin improved to 39.3% from 38.1%. Free cash flow TTM is $284M, providing some financial flexibility. The implied upside to analyst targets is +29% based on forward PE of 21.0x and estimated EPS of $1.535. Compared to the industry, Elanco's PS is typical for specialty pharma, but its growth rate justifies a premium.
Risks & Conditions: The biggest risks are failure to achieve sustained profitability and high debt levels. This Buy would downgrade to Hold if revenue growth decelerates below 5% YoY or if gross margins fall below 35%. Upgrade to Strong Buy if the company reports positive net income for two consecutive quarters. Valuation verdict: Elanco is fairly valued relative to its growth prospects but undervalued relative to its historical PS range, offering a favorable risk/reward for patient investors.
Sign up to view all
ELAN 12-Month Price Forecast
Elanco's strong revenue growth, improving margins, and attractive valuation relative to its history support a bullish stance. The stock has significant upside to analyst targets and is benefiting from a successful turnaround. However, the lack of profitability and high debt levels temper confidence. The base case of gradual improvement is most likely, but the bull case could materialize if the company achieves positive net income. We would upgrade to high confidence if Elanco reports two consecutive quarters of profitability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $32.67 and implied upside of +30.0% versus the current price.
Average Target
$32.67
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$20 - $33
Analyst target range
Elanco is covered by 5 analysts, with a consensus leaning bullish. The average EPS estimate for the current fiscal year is $1.535, with a low of $1.501 and high of $1.564. The average revenue estimate is $6.045B. While explicit price targets are not provided, the implied upside can be inferred: with a forward PE of 21.0x and estimated EPS of $1.535, the implied price is $32.24, suggesting approximately +29% upside from the current $25.00. The consensus recommendation is likely Overweight/Buy based on recent ratings from Keybanc, Morgan Stanley, Leerink, JP Morgan, and Piper Sandler, all maintaining positive stances. The target range (low to high) is not explicitly given, but the EPS range of $1.501–$1.564 implies a price range of $31.52–$32.84 using the forward PE. The high target assumes continued product momentum and margin expansion, while the low target factors in potential headwinds from competition or cost pressures. Recent upgrades from Piper Sandler (Neutral to Overweight) and JP Morgan (Neutral to Overweight) in late 2025/early 2026 signal growing confidence. The narrow EPS range suggests relatively high conviction among analysts.
Bulls vs Bears: ELAN Investment Factors
Elanco presents a compelling turnaround story with strong revenue growth, improving margins, and significant upside to analyst targets. The stock has outperformed the market by a wide margin and trades at a discount to its historical valuation. However, persistent net losses, high debt, and sequential revenue deceleration are key concerns. The bull case currently has stronger evidence, driven by product momentum and raised guidance, but the sustainability of margin improvement and debt reduction remains the single most important tension. If Elanco can continue to execute and deliver profitability, the stock could re-rate higher; failure to do so could lead to a sharp pullback.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 12.2% YoY to $1.144B, and the company raised guidance after Q1 2026 earnings. This demonstrates product momentum and successful turnaround execution, supported by recent analyst upgrades from Piper Sandler and JP Morgan.
- Attractive Valuation vs. History: The trailing PS ratio of 2.38x is near the lower end of its historical range (3.67x to 13.74x), suggesting the stock is relatively cheap compared to its own past. This could present a value opportunity if growth sustains.
- Significant Upside to Analyst Targets: With a forward PE of 21.0x and estimated EPS of $1.535, the implied price is $32.24, offering approximately +29% upside from the current $25.00. The consensus is bullish with 5 analysts maintaining positive ratings.
- Improving Gross Margin Trend: Gross margin improved to 39.3% in Q4 2025 from 38.1% in Q4 2024, indicating better cost management. The trailing twelve-month gross margin is 43.5%, reflecting operational efficiencies from the turnaround plan.
Bearish
- Persistent Net Losses and Negative ROE: Elanco reported a net loss of -$276M in Q4 2025, swinging from a profit of $67M in Q1 2025. The ROE is -3.5%, reflecting ongoing profitability challenges despite revenue growth.
- High Debt Burden and Interest Costs: Debt-to-equity is 0.61, and interest expense was $91M in Q4 2025, up from $62M a year ago. The company relies on debt financing, and free cash flow declined to $46M in Q4 2025 from $180M in Q2 2025.
- Sequential Revenue Deceleration: Revenue declined from $1.241B in Q2 2025 to $1.144B in Q4 2025, a drop of 7.8%. This sequential deceleration raises questions about the sustainability of growth and could lead to analyst downgrades.
- Elevated Valuation Multiples vs. Profitability: The trailing PE is -48.1x (not meaningful), and EV/EBITDA is 21.8x, which is high for a company with negative net income. The market is pricing in future profitability, leaving little room for error.
ELAN Technical Analysis
Elanco is in a sustained uptrend, with a 1-year price change of +69.8%, significantly outperforming the S&P 500's +19.1%. The current price of $25.00 sits at 90.2% of its 52-week range ($13.39–$27.72), indicating strong momentum but also proximity to resistance near the 52-week high. This positioning suggests bullish sentiment, though the stock may be approaching overbought levels. Short-term momentum is accelerating: the 1-month change is +5.8% versus the S&P 500's -1.3%, while the 3-month change is +8.3% versus the S&P 500's +13.6%. The 1-month relative strength of +7.0% confirms near-term outperformance, but the 3-month relative strength of -5.2% hints at a deceleration relative to the broader market. This divergence could signal a potential pullback or consolidation after a strong run. Key support is at the 52-week low of $13.39, while resistance is at the 52-week high of $27.72. A breakout above $27.72 would signal a continuation of the uptrend, while a breakdown below recent support near $22 could indicate a reversal. With a beta of 1.685, Elanco is 68.5% more volatile than the S&P 500, implying higher risk and potential for larger swings, which is critical for position sizing.
Beta
1.69
1.69x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$13-$28
Price range past year
Annual Return
+71.7%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | +6.3% | +1.9% |
| 3m | +10.2% | +14.0% |
| 6m | +10.0% | +8.9% |
| 1y | +71.7% | +20.1% |
| ytd | +11.6% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Revenue has shown a mixed trajectory: Q4 2025 revenue was $1.144B, up 12.2% YoY from $1.02B in Q4 2024, but down from Q2 2025's $1.241B. The multi-quarter trend shows deceleration from Q1 2025's $1.193B and Q2 2025's $1.241B, with Q3 2025 at $1.137B and Q4 2025 at $1.144B. Segment data reveals Farm Animal revenue of $640M (including Cattle $296M, Poultry $237M, Swine $107M) and Pet Health of $489M, indicating a diversified portfolio. The growth is driven by product momentum, but the sequential decline from Q2 to Q4 raises questions about sustainability. Profitability remains challenged: net income was -$276M in Q4 2025, swinging from a profit of $67M in Q1 2025. Gross margin improved to 39.3% in Q4 2025 from 38.1% in Q4 2024, but remains below the 46.6% in Q1 2025. The net margin was -24.1% in Q4 2025, reflecting elevated costs and interest expenses. The company is unprofitable on a trailing basis, but the trajectory shows narrowing losses from -$276M in Q4 2025 versus -$8M in Q4 2024, though the comparison is distorted by one-time items. Balance sheet health is moderate: debt-to-equity is 0.61, and the current ratio is 2.17, indicating adequate liquidity. Free cash flow TTM is $284M, but Q4 2025 FCF was only $46M, down from $180M in Q2 2025. ROE is negative at -3.5%, reflecting persistent losses. The company generates positive operating cash flow ($108M in Q4 2025) but relies on debt financing for growth, as seen in debt repayment of $562M in Q4 2025.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.39%
Latest Quarter
Free Cash Flow
$284000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Since net income is negative (TTM EPS -$0.02), the trailing PE is not meaningful (-48.1x). Therefore, we lead with the price-to-sales (PS) ratio. The trailing PS is 2.38x, while the forward PS (based on estimated revenue of $6.045B) is approximately 1.86x. The gap between trailing and forward PS implies the market expects revenue growth, which aligns with the 12.2% YoY growth in Q4 2025. Compared to the industry average PS (not provided), Elanco's PS of 2.38x is typical for a specialty pharmaceutical company with growth prospects. The EV/Sales multiple of 3.34x suggests a moderate premium relative to peers, likely justified by its market position and product pipeline. Historically, Elanco's PS ratio has ranged from 3.67x (Q1 2023) to 13.74x (Q3 2021). The current PS of 2.38x is near the lower end of its historical range, indicating that the stock is relatively cheap compared to its own history. This could reflect past overvaluation or current undervaluation, but given the recent turnaround, it may present a value opportunity if growth sustains.
PE
-48.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -240x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Elanco's primary financial risk is its persistent unprofitability, with a net loss of -$276M in Q4 2025 and a trailing net margin of -4.9%. The company carries significant debt (debt-to-equity 0.61), and interest expense of $91M in Q4 2025 consumes a large portion of operating cash flow. Free cash flow has been volatile, dropping from $180M in Q2 2025 to $46M in Q4 2025, raising concerns about the company's ability to service debt while investing in growth. The negative ROE of -3.5% indicates that shareholder equity is being eroded, which could limit future financing options.
Market & Competitive Risks: Elanco operates in a competitive animal health market with large players like Zoetis and Merck Animal Health. The stock's beta of 1.685 implies high sensitivity to market downturns, and the 3-month relative strength of -5.2% suggests recent underperformance. Valuation risk is present: the EV/EBITDA of 21.8x is elevated for a company with negative net income, and any disappointment in earnings could trigger multiple compression. Regulatory risks include changes in FDA approval processes for animal drugs, which could delay product launches.
Worst-Case Scenario: In a severe downturn, Elanco could face a perfect storm of revenue deceleration, margin compression, and debt covenant breaches. If the company fails to achieve profitability and growth stalls, the stock could fall to its 52-week low of $13.39, representing a -46.4% decline from the current price of $25.00. This scenario would likely involve analyst downgrades, a loss of investor confidence, and potential equity dilution to manage debt.
FAQ
The key risks are: 1) Financial: persistent net losses (net margin -4.9% TTM) and high debt (debt-to-equity 0.61) could strain cash flow. 2) Competitive: the animal health market is dominated by larger players like Zoetis, and Elanco may struggle to gain market share. 3) Macro: with a beta of 1.685, the stock is highly sensitive to market downturns. 4) Company-specific: revenue deceleration from $1.241B in Q2 2025 to $1.144B in Q4 2025 raises concerns about growth sustainability. The most severe risk is a failure to achieve profitability, which could lead to a -46% decline to the 52-week low of $13.39.
The 12-month outlook is cautiously bullish. The base case (50% probability) sees the stock trading between $24 and $28, driven by gradual margin improvement and stable growth. The bull case (30% probability) targets $28-$33, assuming sustained revenue growth above 10% and positive net income. The bear case (20% probability) sees the stock falling to $14-$20 if growth decelerates and margins contract. The most likely scenario is the base case, with the stock gradually appreciating toward the analyst average target of $32.24, but near-term volatility may persist.
ELAN appears undervalued relative to its own history. The trailing PS ratio of 2.38x is well below the historical range of 3.67x to 13.74x, suggesting the stock is cheap compared to its past. The forward PS of 1.86x implies the market expects revenue growth, which is supported by the 12.2% YoY increase. However, on an earnings basis, the stock is not cheap: the trailing PE is negative, and EV/EBITDA of 21.8x is elevated. Overall, the valuation is reasonable for a growth turnaround, but investors are paying for future profitability.
ELAN offers a compelling risk/reward for investors with a medium-term horizon. The stock has strong product momentum, with Q4 2025 revenue growing 12.2% YoY, and trades at a forward PS of 1.86x, near the low end of its historical range. Analyst targets imply ~29% upside from the current price of $25.00. However, the company is unprofitable (net loss of -$276M in Q4 2025) and carries significant debt (debt-to-equity 0.61). It is a good buy for investors who believe in the turnaround story and can tolerate volatility, but those seeking stable income or low risk should wait for sustained profitability.
ELAN is better suited for medium- to long-term investment. The stock's high beta (1.685) and recent price momentum (+69.8% over 1 year) make it attractive for short-term traders, but the turnaround story requires time to play out. The company is not yet profitable, and debt reduction will take several quarters. A minimum holding period of 12-18 months is recommended to allow for margin improvement and potential analyst upgrades. Long-term investors should monitor free cash flow and debt levels as key indicators of success.